“Unique trend” and “contradictory trend” in discrimination of primary synchronous lung cancer and metastatic lung cancer

BMC Cancer

Cheng Shen¹  Huan Xu²  Lunxu Liu¹  Yubin Zhou¹  Dali Chen¹  Heng Du¹  Zhaojie Han¹  Guowei Che¹ 

[1] Department of Cardiovascular and Thoracic Surgery, West-China Hospital, Sichuan University, Chengdu 610041, China

[2] Department of Pathology, West-China Hospital, Sichuan University, Chengdu 610041, China

关键词: Microsatellite analysis;    Metastatic lung cancer;    Primary synchronous lung cancer;   

Others  :  1079525
DOI  :  10.1186/1471-2407-13-467

 received in 2013-03-13, accepted in 2013-10-01,  发布年份 2013

【 摘 要 】

Background

Distinguishing between multiple primary lung cancers and metastatic tumors is often difficult when the tumor histology is same. Since genomic instability is a common feature of cancer, we hypothesized that independently arising neoplasms in an individual patient would exhibit measurable genomic variation, enabling discrimination of tumor lineage and relatedness. The feasibility of analyzing genomic instability expression profiles to distinguish multiple primary lung cancers from metastatic tumors was evaluated.

Methods

This study enrolled 13 patients, with multiple primary lung cancers demonstrating with the histology, who underwent surgery between April 2003 and December 2012 at the Department of the Thoracic Surgery at West China Hospital in Sichuan province of China and 10 patients who were diagnosed as metastasis disease during the same period for comparison purposes. Genomic DNA from lung cancers from individual patients was analyzed by six microsatellites (D2S1363, D6S1056, D7S1824, D10S1239, D15S822, and D22S689) with PCR to identify discordant allelic variation. The experiments were approved by the West China Hospital Ethics committee (No.2013 (33)) and all patients agreed to participate in the study and signed an informed consent form.

Results

All of the 10 patients with distant metastasis showed a consistent consequence that we called “unique trend” between primary tumor and distant metastasis. The “trend” is representive in this study, which means that all alleles corresponding to six microsatellite markers were detected in DNA from primary tumors but were reduced or not observed in DNA from metastatic tumors. In the group of synchronous lung tumor with different histological types, the result showed a “contradictory trend”. Some alleles were detected in DNA from primary tumors but were reduced or not observed in DNA from metastatic tumors and other alleles corresponding to six microsatellite markers were detected in DNA from metastatic tumors but were reduced or not observed in DNA from primary tumors. In the third group (synchronous lung tumor with same histological types), 2 of 8 patients showed “unique trend” and the others showed “contradictory trend”.

Conclusions

With polymorphic microsatellite markers, the “unique trend” that represents metastasis cancers and the “contradictory trend” that represents primary multiple tumors are useful in the diagnosis between tumors found at the same time in the pulmonary even diagnosed with the histopathological evaluation from a single patient.

【 授权许可】

   
2013 Shen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Ferguson MK, DeMeester TR, DesLauriers J, Little AG, Piraux M, Golomb H: Diagnosis and management of synchronous lung cancers. J Thorac Cardiovasc Surg 1985, 89:378-385.
• [2]Verhagen AF, van de Wal HJ, Cox AL, Lacquet LK: Surgical treatment of multiple primary lung cancers. Thorac Cardiovasc Surg 1989, 37:107-111.
• [3]Lam S, MacAulay C, Palcic B: Detection and localization of early lung cancer by imaging techniques. Chest 1993, 103:12-14.
• [4]Woolner LB, Fontana RS, Cortese DA, Sanderson DR, Bernatz PE, Payne WS, Pairolero PC, Piehler JM, Taylor WF: Roentgenographically occult lung cancer: pathologic findings and frequency of multicentricity during a 10-year period. Mayo Clin Proc 1984, 59:453-466.
• [5]van Rens MT, Zanen P, Brutel de La Rivière A, Elbers HR, van Swieten HA, van Den Bosch JM: Survival in synchronous vs single lung cancer: upstaging better reflects prognosis. Chest 2000, 118:952-958.
• [6]Che GW, Zhou QH: Modern ideas on the surgery treatment for multiple cancers of lung. Nat Med J China 2007, 87:1653-1655. [in Chinese]
• [7]Osaki T, Yoneda K, Yamamoto T, Kimura T, Matuoka H, Sakai H, Ryoke K: Clinical investigation on pulmonary metastasis of head and neck carcinomas. Oncology 2000, 59:196-203.
• [8]Mercer RR, Lucas NC, Simmons AN, Zander DS, Tsongalis GJ, Funkhouser WK, Coleman WB: Molecular discrimination of multiple primary versus metastatic squamous cell cancers of the head/neck and lung. Exp Mol Pathol 2009, 86:1-9.
• [9]Sozzi G, Miozzo M, Pastorino U, Pilotti S, Donghi R, Giarola M, De Gregorio L, Manenti G, Radice P, Minoletti F: Genetic evidence for an independent origin of multiple preneoplastic and neoplastic lung lesions. Cancer Res 1995, 55:135-140.
• [10]Flynn MJ, Rassl D, El Shahira A, Higgins B, Barnard S: Metachronous and synchronous lung tumors: five malignant lung pathologies in 1 patient during 7 years. Ann Thorac Surg 2004, 78:2154-2155.
• [11]Shimizu S, Yatabe Y, Koshikawa T, Haruki N, Hatooka S, Shinoda M, Suyama M, Ogawa M, Hamajima N, Ueda R, Takahashi T, Mitsudomi T: High frequency of clonally related tumors in cases of multiple synchronous lung cancers as revealed by molecular diagnosis. Clin Cancer Res 2000, 10:3994-3999.
• [12]Pommier RF, Vetto JT, Lee JT, Johnston KM: Synchronous non-small cell lung cancers. Am J Surg 1996, 171:521-524.
• [13]Mathisen DJ, Jensik RJ, Faber LP, Kittle CF: Survival following resection for second and third primary lung cancers. J Thorac Cardiovasc Surg 1984, 88:502-510.
• [14]Rosengart TK, Martini N, Ghosn P, Burt M: Multiple primary lung carcinomas: prognosis and treatment. Ann Thorac Surg 1991, 52:773-779.
• [15]Coleman WB, Tsongalis GJ: Molecular mechanisms of human carcinogenesis. EXS 2006, 96:321-349.
• [16]Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57-70.
• [17]Rai R, Peng G, Li K, Lin SY: DNA damage response: the players, the network and the role in tumor suppression. Cancer Genomics Proteomics 2007, 4:99-106.
• [18]Martini N, Melamed MR: Multiple primary lung cancers. J Thorac Cardiovasc Surg 1975, 70:606-612.
• [19]Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH: A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Res 2003, 63:1727-1730.
• [20]Kawaguchi T, Matsumura A, Iuchi K, Ishikawa S, Maeda H, Fukai S, Komatsu H, Kawahara M: Second primary cancers in patients with stage III non-small cell lung cancer successfully treated with chemo-radiotherapy. Jpn J Clin Oncol 2006, 36:7-11.
• [21]Haraguchi S, Koizumi K, Hioki M, Hisayoshi T, Hirata T, Shimizu K: Hereditary factors in multiple primary malignancies associated with lung cancer. Surg Today 2007, 37:375-378.
• [22]Reichel MB, Ohgaki H, Petersen I, Kleihues P: p53 mutations in primary human lung tumors and their metastases. Mol Carcinog 1994, 9:105-109.
• [23]Chung KY, Mukhopadhyay T, Kim J, Casson A, Ro JY, Goepfert H, Hong WK, Roth JA: Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. Cancer Res 1993, 53:1676-1683.
• [24]Gasparotto D, Maestro R, Barzan L, Vukosavljevic T, Doglioni C, Sulfaro S, Piccinin S, Boiocchi M: Recurrences and second primary tumours in the head and neck region: differentiation by p53 mutation analysis. Ann Oncol 1995, 6:933-939.
• [25]Froio E, D’Adda T, Fellegara G, Ampollini L, Carbognani P, Rindi G: Three different synchronous primary lung tumours: a case report with extensive genetic analysis and review of the literature. Lung Cancer 2008, 59:395-402.
• [26]Geurts TW, Nederlof PM, van den Brekel MW, van’t Veer LJ, de Jong D, Hart AA, van Zandwijk N, Klomp H, Balm AJ, van Velthuysen ML: Pulmonary squamous cell carcinoma following head and neck squamous cell carcinoma: metastasis or second primary? Clin Cancer Res 2005, 11:6608-6614.